{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:36:04Z","timestamp":1758634564351,"version":"3.37.3"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,5,21]],"date-time":"2014-05-21T00:00:00Z","timestamp":1400630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tacrolimus exposure and renal function data to 36\u00a0months post\u2010transplant were analyzed from the prospective, observational <jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content><\/jats:italic>ycophenolic acid <jats:italic><jats:styled-content style=\"fixed-case\">O<\/jats:styled-content><\/jats:italic>bservational <jats:italic><jats:styled-content style=\"fixed-case\">RE<\/jats:styled-content><\/jats:italic>nal transplant (<jats:styled-content style=\"fixed-case\">MORE<\/jats:styled-content>) registry in which <jats:italic>de novo<\/jats:italic> kidney transplant patients were managed according to local practice. Tacrolimus trough (<jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>) concentration at month 12 was stratified as low (&lt;6\u00a0ng\/mL), moderate (6\u20138\u00a0ng\/mL), or high (&gt;8\u00a0ng\/mL) in 724 patients. Estimated glomerular filtration rate (e<jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content>) was stratified as low (&lt;60\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>) or high (\u226560\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>). High tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> (&gt;8\u00a0ng\/mL) was observed in 47.7%, 34.1%, 26.8%, and 26.7% of patients at baseline and months 12, 24, and 36, respectively. Biopsy\u2010proven acute rejection was similar to month 36 regardless of tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> category at month 12. Tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> &gt;8\u00a0ng\/mL vs. &lt;6\u00a0ng\/mL at month 12 was predictive of low e<jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content> at month 24 (p\u00a0=\u00a00.023) with a nonsignificant trend at month 36 (p\u00a0=\u00a00.085). Infections (p\u00a0&lt;\u00a00.013) and BK virus infection (p\u00a0&lt;\u00a00.001) were most frequent in the low tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> cohort. Neutropenia was most frequent in the high tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> category (p\u00a0=\u00a00.010). In conclusion, over a quarter of patients were exposed to high tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> to 36\u00a0months post\u2010transplant. Tacrolimus exposure did not affect rejection risk, but tacrolimus <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> &gt;8\u00a0ng\/mL at month 12 was predictive of subsequent low e<jats:styled-content style=\"fixed-case\">GFR<\/jats:styled-content> compared to <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> &lt;6\u00a0ng\/mL.<\/jats:p>","DOI":"10.1111\/ctr.12377","type":"journal-article","created":{"date-parts":[[2014,4,23]],"date-time":"2014-04-23T10:18:01Z","timestamp":1398248281000},"page":"768-775","source":"Crossref","is-referenced-by-count":7,"title":["Tacrolimus exposure in the real world: an analysis from the <scp>M<\/scp>ycophenolic acid <scp>O<\/scp>bservational <scp>RE<\/scp>nal transplant study"],"prefix":"10.1111","volume":"28","author":[{"given":"Fuad S.","family":"Shihab","sequence":"first","affiliation":[{"name":"Division of Nephrology University of Utah School of Medicine Salt Lake City UT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Olyaei","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Wiland","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"McCague","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Norman","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,21]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"United States Renal Data System Annual Report 2012. Available athttp:\/\/www.usrds.org\/2012\/pdf\/v2_ch7_12.pdfAccessed 18 March 2013."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91970-0"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04800908"},{"issue":"3","key":"e_1_2_6_5_1","first-page":"S131","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03338.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-13-68"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31817442cf"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02668.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067411"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN107227"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02726.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2004.00318.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31821fad06"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000251807.72246.7d"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2012.01694.x"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12377","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:30:08Z","timestamp":1696365008000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,21]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/ctr.12377"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12377","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"type":"print","value":"0902-0063"},{"type":"electronic","value":"1399-0012"}],"subject":[],"published":{"date-parts":[[2014,5,21]]}}}